PKSmart: An Open-Source Computational Model to Predict Pharmacokinetics of Small Molecules

Srijit Seal,Maria-Anna Trapotsi,Vigneshwari Subramanian,Ola Spjuth,Nigel Greene,Andreas Bender

DOI: https://doi.org/10.1101/2024.02.02.578658

2024-02-07

Abstract:Drug exposure is a key contributor to the safety and efficacy of drugs. It can be defined using human pharmacokinetics (PK) parameters that affect the blood concentration profile of a drug, such as steady-state volume of distribution (VDss), total body clearance (CL), half-life (t½), fraction unbound in plasma (fu) and mean residence time (MRT). In this work, we used molecular structural fingerprints, physicochemical properties, and predicted animal PK data as features to model the human PK parameters VDss, CL, t½, fu and MRT for 1,283 unique compounds. First, we predicted animal PK parameters [VDss, CL, fu] for rats, dogs, and monkeys for 372 unique compounds using molecular structural fingerprints and physicochemical properties. Second, we used Morgan fingerprints, Mordred descriptors and predicted animal PK parameters in a hyperparameter-optimised Random Forest algorithm to predict human PK parameters. When validated using repeated nested cross-validation, human VDss was best predicted with an R of 0.55 and a Geometric Mean Fold Error (GMFE) of 2.09; CL with accuracies of R =0.31 and GMFE=2.43, fu with R =0.61 and GMFE=2.81, MRT with R =0.28 and GMFE=2.49, and t½ with R =0.31 and GMFE=2.46 for models combining Morgan fingerprints, Mordred descriptors and predicted animal PK parameters. We evaluated models with an external test set comprising 315 compounds for VDss (R =0.33 and GMFE=2.58) and CL (R =0.45 and GMFE=1.98). We compared our models with proprietary pharmacokinetic (PK) models from AstraZeneca and found that model predictions were similar with Pearson correlations ranging from 0.77-0.78 for human PK parameters of VDss and fu and 0.46-0.71 for animal (dog and rat) PK parameters of VDss, CL and fu. To the best of our knowledge, this is the first work that publicly releases PK models on par with industry-standard models. Early assessment and integration of predicted PK properties are crucial, such as in DMTA cycles, which is possible with models in this study based on the input of only chemical structures. We developed a webhosted application PKSmart ( ) which users can access using a web browser with all code also downloadable for local use.

Bioinformatics

What problem does this paper attempt to address?

This paper aims to address the issue of predicting pharmacokinetic (PK) parameters of drugs in vivo. Specifically, the researchers utilized the structural fingerprints, physicochemical properties of small molecule compounds, and predicted animal PK data as features to establish models for predicting human PK parameters, including steady-state volume of distribution (VDss), total clearance (CL), half-life (t½), unbound fraction in plasma (fu), and mean residence time (MRT). The study optimized hyperparameters using the random forest algorithm and evaluated model performance through repeated nested cross-validation. Additionally, the study developed a web application named PKSmart, which users can access via a browser, and all the code is available for download for local use. This is the first public release of PK models comparable to industry-standard models, which is significant for early assessment and integration of predicted PK properties, especially in the design-make-test-analyze (DMTA) cycle.

PKSmart: An Open-Source Computational Model to Predict Pharmacokinetics of Small Molecules

Computational Predictions of Nonclinical Pharmacokinetics at the Drug Design Stage

Application of Ivive and Pbpk Modeling in Prospective Prediction of Clinical Pharmacokinetics: Strategy and Approach During the Drug Discovery Phase with Four Case Studies

Machine learning framework to predict pharmacokinetic profile of small molecule drugs based on chemical structure

Actionable predictions of human pharmacokinetics at the drug design stage

pkCSM: Predicting Small-Molecule Pharmacokinetic and Toxicity Properties Using Graph-Based Signatures

Model-based Target Pharmacology Assessment (mTPA): An Approach Using PBPK/PD Modeling and Machine Learning to Design Medicinal Chemistry and DMPK Strategies in Early Drug Discovery

Pharmacokinetics Profiler (PhaKinPro): Model Development, Validation, and Implementation as a Web Tool for Triaging Compounds with Undesired Pharmacokinetics Profiles

Shared learning from a physiologically based pharmacokinetic modeling strategy for human pharmacokinetics prediction through retrospective analysis of Genentech compounds

PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: Prediction of plasma concentration–time profiles in human by using the physiologically‐based pharmacokinetic modeling approach

Evaluation of the Success of High-Throughput Physiologically Based Pharmacokinetic (HT-PBPK) Modeling Predictions to Inform Early Drug Discovery

A Combination of Machine Learning and PBPK Modeling Approach for Pharmacokinetics Prediction of Small Molecules in Humans

Prediction of human pharmacokinetic parameters incorporating SMILES information

PK/DB: database for pharmacokinetic properties and predictive in silico ADME models

Predicting pharmacodynamic effects through early drug discovery with artificial intelligence-physiologically based pharmacokinetic (AI-PBPK) modelling

PK-DB: pharmacokinetics database for individualized and stratified computational modeling

PhRMA CPCDC Initiative on Predictive Models of Human Pharmacokinetics, Part 1: Goals, Properties of the Phrma Dataset, and Comparison with Literature Datasets

Systematic Evaluation of High-Throughput PBK Modelling Strategies for the Prediction of Intravenous and Oral Pharmacokinetics in Humans

Prediction of human CNS pharmacokinetics using a physiologically-based pharmacokinetic modeling approach

A fully automatic tool for development of population pharmacokinetic models

Evaluation of Generic Methods to Predict Human Pharmacokinetics Using Physiologically Based Pharmacokinetic Model for Early Drug Discovery of Tyrosine Kinase Inhibitors